Primary liver cancer includes hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Incidence of liver cancer has been increasing in recent years, and the 5-year survival is <20%. HCC and CCA are often accompanied with a dense stroma coupled with infiltrated immune cells, which is referred to as the tumor microenvironment. Populations of specific immune cells, such as high density of CD163+ macrophages and low density of CD8+ T cells, are associated with prognosis and survival rates in both HCC and CCA. Immune cells in the tumor microenvironment can be a therapeutic target for liver cancer treatments. Previous studies have introduced immunotherapy using immune checkpoint inhibitors, pulsed dendritic cells, or transduced T cells, to enhance cytotoxicity of immune cells and inhibit tumor growth. This review summarizes current understanding of the roles of immune cells in primary liver cancer covering HCC and CCA. (Am J Pathol 2022, 192: 826-836; https://doi.org/10.1016/ j.ajpath.2022.02.004)
The functional roles of immune cells in primary liver cancer / Pham, Linh; Kyritsi, Konstantina; Zhou, Tianhao; Ceci, Ludovica; Baiocchi, Leonardo; Kennedy, Lindsey; Chakraborty, Sanjukta; Glaser, Shannon; Francis, Heather; Alpini, Gianfranco; Sato, Keisaku. - In: THE AMERICAN JOURNAL OF PATHOLOGY. - ISSN 0002-9440. - 192:6(2022), pp. 826-836. [10.1016/j.ajpath.2022.02.004]
The functional roles of immune cells in primary liver cancer
Ceci, Ludovica;Alpini, Gianfranco;
2022
Abstract
Primary liver cancer includes hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Incidence of liver cancer has been increasing in recent years, and the 5-year survival is <20%. HCC and CCA are often accompanied with a dense stroma coupled with infiltrated immune cells, which is referred to as the tumor microenvironment. Populations of specific immune cells, such as high density of CD163+ macrophages and low density of CD8+ T cells, are associated with prognosis and survival rates in both HCC and CCA. Immune cells in the tumor microenvironment can be a therapeutic target for liver cancer treatments. Previous studies have introduced immunotherapy using immune checkpoint inhibitors, pulsed dendritic cells, or transduced T cells, to enhance cytotoxicity of immune cells and inhibit tumor growth. This review summarizes current understanding of the roles of immune cells in primary liver cancer covering HCC and CCA. (Am J Pathol 2022, 192: 826-836; https://doi.org/10.1016/ j.ajpath.2022.02.004)File | Dimensione | Formato | |
---|---|---|---|
Pham_Functional_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
907.88 kB
Formato
Adobe PDF
|
907.88 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.